Navigation Links
Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid
Date:7/17/2009

all TSX requirements for continued listing, failing which the Share will be delisted from the TSX 30 days thereafter. The Corporation is, therefore, considering its options in this regard, which may include applying for a transfer of its listing to the TSX Venture Exchange or the NEX Board of the TSX Venture Exchange. Any decision in this regard will be made well in advance of the TSX deadline.

About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)

Bradmer Pharmaceuticals' lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. Bradmer initiated enrollment of primary GBM patients in a Phase III multi-center clinical trial of Neuradiab. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.

Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regula
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Bradmer announces 2009 first quarter operational and financial results
2. Bradmer announces 2008 fourth quarter and fiscal year operational and financial results
3. Bradmer implements cash conservation plan
4. Bradmer provides clinical trial update and announces evaluation of strategic alternatives
5. Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference
6. Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting
7. Bradmer announces 2008 third quarter operational and financial results
8. Bradmer to present at Rodman & Renshaw Healthcare Conference
9. Bradmer receives FDA approval to proceed with Phase III clinical trial
10. Bradmer announces 2008 first quarter operational and financial results
11. Bradmer announces new additions to management team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... (PRWEB) August 27, 2014 iHire ... practices as the “Most Creative Workplace” in Frederick, ... Best Places to Work Awards. , Held at ... event is a joint partnership between the Frederick ... Economic Development, Frederick County Business Development and Retention, ...
(Date:8/26/2014)... August 27, 2014 Carol Fenster, a ... 100 Best Quick Gluten-Free Recipes (Houghton Mifflin Harcourt, ... , Fenster believes that cooking gluten-free food can ... today’s busy lifestyle doesn’t leave much time for food ... cooks ask me is how to shorten their time ...
(Date:8/26/2014)... (PRWEB) August 27, 2014 There are ... affluent, however the reality is cruel. Some people, especially ... clothes, may not save enough money to be affluent. ... is delighted to announce its new catalog, Flash Deals ... dresses, bags, outdoor accessories and more from this company ...
(Date:8/26/2014)... (PRWEB) August 26, 2014 AttorneyOne.com, a recognized ... latest information from the FDA on Gel-E Donut and ... August 22, that Gel-E Donut and Squishon 2 gel-filled products, ... complaints about visible mold. Gel E-Donut and Squishon 2 are ... and/or body, help ease pressure caused by long periods of ...
(Date:8/26/2014)... TX (PRWEB) August 26, 2014 ... it simply makes sense to use hearing protection ... losing hearing forever. There are many different forms ... Employers generally provide hearing protection training and devices ... other noisy industries. The National Institute of Occupational ...
Breaking Medicine News(10 mins):Health News:iHire Named Most Creative Workplace in Frederick, MD 2Health News:Gluten-Free Expert Carol Fenster Announces New Cookbook for Quick Meals 2Health News:Gluten-Free Expert Carol Fenster Announces New Cookbook for Quick Meals 3Health News:Become a Rich Person Right Away By Taking Advantage Of Fecbek.com's Flash Deals 2Health News:Gel-E Donut and Squishon 2 Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:San Antonio Hearing Centers Now Offering a Full Line of Occupational Hearing Protection Products 2Health News:San Antonio Hearing Centers Now Offering a Full Line of Occupational Hearing Protection Products 3
... Cholesterol-lowering drugs known as statins are among the ... study by researchers at Fred Hutchinson Cancer Research Center ... from one of the most serious complications of the ... are reported in the Nov. 4 first edition of ...
... ... Product in Scottsdale , ... (Vocus) December 4, 2009 -- A valley inventor garnering national attention with an ... boost productivity will be showcasing the product at Saturday’s Technology Fair located at the ...
... , WASHINGTON, Dec. 4 As Congress ... Research Council (FRC) today announced an eight week campaign to ... on provisions of the Senate health care bill. These ... or the public option. Survey participants who express opposition ...
... JEFFERSON CITY, Mo., Dec. 4 Farmers Insurance Missouri State Executive ... the CEO and creator of a children,s fire safety program sponsored ... conduct a children,s fire safety day at the Missouri Capitol December ... call for fire safety comes following a tragic fire that took ...
... Journal of Neurosurgery: Pediatrics finds that operative plans ... thalamus of the brain can be augmented with Diffusion Tensor ... for the visualization of nerve fiber bundles in the brain. ... the tumor while avoiding damage to the fiber bundles that ...
... ... to enhance consumers’ quality of life, today announced that it has been awarded the ... HealthiFeet®. , ... (PRWEB) December 4, 2009 -- Tender Corp., a leading manufacturer of over-the-counter topical cream ...
Cached Medicine News:Health News:Cholesterol-lowering drugs also may protect stem cell transplant patients from GVHD 2Health News:Valley Health Invention Making National Splash Showcased at Scottsdale Civic Center Gallery 2Health News:FRC Announces Campaign to Call Every Louisiana Household, Urging Opposition to Health Care Takeover 2Health News:Missouri Safety Day at the Capitol 2Health News:Tender Corp.'s HealthiFeet Awarded American Podiatric Medical Association Seal of Approval 2Health News:Tender Corp.'s HealthiFeet Awarded American Podiatric Medical Association Seal of Approval 3Health News:Tender Corp.'s HealthiFeet Awarded American Podiatric Medical Association Seal of Approval 4
(Date:8/26/2014)... and LONDON , August 26, 2014 ... FDNA Inc. ( http://www.fdna.com ) and London Medical Databases ... partnered to offer, for the first time, online access ... FDNA, developer of the Facial Dysmorphology ... collection into Face2Gene [ TM ] , ...
(Date:8/26/2014)... SAN DIEGO , Aug. 26, 2014   ... M.D., has been named vice president, clinical development, and ... president, clinical operations. "As we advance ... we are expanding our clinical team with individuals who ... and commercialization activities," said Jamey Skillings , M.D., ...
(Date:8/26/2014)... , Aug. 26, 2014  Zimmer Holdings, Inc. (NYSE ... announced that its Board of Directors has approved the payment ... quarter of 2014. The cash dividend of ... 31, 2014, to stockholders of record as of the close ... are subject to approval of the Board of Directors and ...
Breaking Medicine Technology:FDNA Partners with London Medical Databases (LMD) to Provide Long-Awaited Online Access to Leading Dysmorphology Database 2FDNA Partners with London Medical Databases (LMD) to Provide Long-Awaited Online Access to Leading Dysmorphology Database 3Tocagen Expands Clinical Development Team; 2Tocagen Expands Clinical Development Team; 3
... DATATRAK International, Inc. (OTCQX: DATA), a technology and services ... trials industry, today announced that it has been awarded ... Organization (CRO) in India, with which the Company had ... order to execute a Phase II study for the ...
... 8, 2011 Vanda Pharmaceuticals Inc. (Nasdaq: ... has granted orphan drug designation for tasimelteon, an oral ... for Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals with ... the designation that the Committee for Orphan Medicinal Products ...
Cached Medicine Technology:DATATRAK Awarded First Study With Kreara Solutions 2DATATRAK Awarded First Study With Kreara Solutions 3Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 2Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 3Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 4
Provides reliable information on the most commonly prescribed drugs, their side effects, interactions and cost of therapy....
Ident-A-Drug gives you quick accurate identification of oral tablets and capsules used in North America....
... latest in scientific clinical trial activity and ... resources from CenterWatch. This highly valuable resource ... and stay abreast of medical breakthroughs on ... Trials, Clinical Trial Results, Newly Approved Drugs, ...
Providing patients and their advocates with a variety of information services and educational materials on clinical research....
Medicine Products: